Oral contraceptive use and measurable cardiovascular risk factors in Korean women aged 20-50 years: The Fourth Korean National Health and Nutrition Examination Survey 2007-2009 (KNHANES IV)

Gynecological Endocrinology

Volumn 29, Issue 7, 2013, Pages 707-711

  Lee, Jung Yun ^a   Ku, Seung Yup ^a   Kim, Seok Hyun ^a   Hwang, Seung Sik ^b   Lee, Hae Won ^a   Park, Sang Min ^a  

^a Seoul National University   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

Cardiovascular risk factors; Korea; Metabolic syndrome; Oral contraceptives; Triglycerides

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PRIORITY JOURNAL; REPRODUCTION; REVIEW; WAIST CIRCUMFERENCE;

ADULT; AGE DISTRIBUTION; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MIDDLE AGED; NUTRITION SURVEYS; REPUBLIC OF KOREA; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84879312832     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.797393     Document Type: Review

References (32)

1. Benagiano G, Bastianelli C, Farris M. Contraception today. Ann N Y Acad Sci 2006;1092:1-32
2. Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. JAMA 1978;240:2548-52
3. Stadel BV. Oral contraceptives and cardiovascular disease (second of two parts). N Engl J Med 1981;305:672-7
4. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003;349:1443-50
5. Lidegaard O, Lokkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257-66
6. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
7. Darney P. Safety and efficacy of a triphasic oral contraceptive containing desogestrel: Results of three multicenter trials. Contraception 1993;48:323-37
8. Kovacs L, Bartfai G, Apro G, et al. The effect of the contraceptive pill on blood pressure: A randomized controlled trial of three progestogen-oestrogen combinations in Szeged, Hungary. Contraception 1986;33:69-77
9. Nichols M, Robinson G, Bounds W, et al. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception 1993;47:367-76
10. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375-81
11. Watanabe RM, Azen CG, Roy S, et al. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J Clin Endocrinol Metab 1994;79:1277-283
12. Hurwitz BE, Henry N, Goldberg RB. Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women: National Health and Nutrition Examination Survey 1999-2004. Gynecol Endocrinol 2009;25: 441-9
13. The fourth Korean National Health and Nutrition Examination Survey: Korea Centers for Disease Control and Prevention (Korea). 2012. Available at http://knhanes.cdc.go.kr/.
14. Kim SH, Kim TH, Hwang HJ. The relationship of physical activity (PA) and walking with sarcopenia in Korean males aged 60 years and older using the Fourth Korean National Health and Nutrition Examination Survey (KNHANES IV-2, 3), 2008-2009. Arch Gerontol Geriatr 2013;56:472-7
15. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: Updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007;39:1423-34
16. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
17. Leblanc ES, Laws A. Benefits and risks of third-generation oral contraceptives. J Gen Intern Med 1999;14:625-32
18. Rosenberg L, Palmer JR, Sands MI, et al. Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol 1997;177: 707-15
19. Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol Metab Clin North Am 2011;40:419-32, i.x.
20. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: Effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2012;4:CD006133
21. Barbagallo M, Dominguez LJ, Licata G, et al. Vascular effects of progesterone: Role of cellular calcium regulation. Hypertension 2001;37:142-7
22. Giribela CR, Melo NR, Silva RC, et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: A prospective clinical trial. Contraception 2012;86: 35-41
23. Berenson AB, Rahman M, Wilkinson G. Effect of injectable and oral contraceptives on serum lipids. Obstet Gynecol 2009;114: 786-94
24. Frempong BA, Ricks M, Sen S, Sumner AE. Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. J Clin Endocrinol Metab 2008;93:2097-103
25. Scharnagl H, Petersen G, Nauck M, et al. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception 2004;69:105-13
26. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115:450-8
27. Sharrett AR, Ballantyne CM, Coady SA, et al. Atherosclerosis Risk in Communities Study G. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13
28. Cagnacci A, Ferrari S, Tirelli A, et al. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: A randomized trial. Contraception 2009;79: 111-6
29. Kim K, Park H. Effect of oral contraceptive use on lipid profile in Korean women aged 35-55 years. Contraception 2012;86: 500-5
30. Krauss RM, Burkman Jr. RT. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992;167:1177-84
31. Petersen KR. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan Med Bull 2002;49:43-60
32. Godsland IF, Crook D, Wynn V. Coronary heart disease risk markers in users of low-dose oral contraceptives. J Reprod Med 1991;36: 226-37